396 related articles for article (PubMed ID: 36271429)
21. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
22. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
[TBL] [Abstract][Full Text] [Related]
24. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
[TBL] [Abstract][Full Text] [Related]
25. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
[TBL] [Abstract][Full Text] [Related]
26. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
Shankaran H; Zhang Y; Tan Y; Resat H
PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
[TBL] [Abstract][Full Text] [Related]
27. Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Ferreira RB; Law ME; Jahn SC; Davis BJ; Heldermon CD; Reinhard M; Castellano RK; Law BK
Oncotarget; 2015 Apr; 6(12):10445-59. PubMed ID: 25865227
[TBL] [Abstract][Full Text] [Related]
28. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
[TBL] [Abstract][Full Text] [Related]
29. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract][Full Text] [Related]
30. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
31. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
32. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Majumder A; Sandhu M; Banerji D; Steri V; Olshen A; Moasser MM
Sci Rep; 2021 Apr; 11(1):9091. PubMed ID: 33907275
[TBL] [Abstract][Full Text] [Related]
33. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
34. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
[TBL] [Abstract][Full Text] [Related]
35. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.
Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H
BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579
[TBL] [Abstract][Full Text] [Related]
36. Targeting HER3 for cancer treatment: a new horizon for an old target.
Uliano J; Corvaja C; Curigliano G; Tarantino P
ESMO Open; 2023 Feb; 8(1):100790. PubMed ID: 36764093
[TBL] [Abstract][Full Text] [Related]
37. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
38. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
39. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.
Khalil HS; Langdon SP; Kankia IH; Bown J; Deeni YY
Oxid Med Cell Longev; 2016; 2016():4148791. PubMed ID: 26770651
[TBL] [Abstract][Full Text] [Related]
40. A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2.
Hassani D; Amiri MM; Mohammadi M; Yousefi P; Judaki MA; Mobini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Shokri F
Curr Res Transl Med; 2021 May; 69(2):103277. PubMed ID: 33639587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]